GET CERTIFIED IN DRUG SAFETY


RECOGNIZED COURSE QUALITY


DESIGNED FOR EXPERTS BY EXPERTS


SELECTING OUTCOMES: SURROGATE ENDPOINTS


OBJECTIVES

This course aims to review the main characteristics of clinically meaningful and surrogate end-points and the advantages and disadvantages of using them in confirmatory phase III clinical trials. The established criteria to assess the validation process of surrogate end-points will also be reviewed.

This course also aims to give you an overview of the different guidelines developed by the FDA and EMA in order to give guidance on the primary end-points to be assessed in confirmatory phase III clinical trials for the different conditions. Some examples of these guidelines will be reviewed.

Surrogate endpoints, Variable, Advantages, Limitations, Use

 

LEARNING OUTCOMES

At the end of this course, you will be familiar with the advantages and limitations of using surrogate endpoints as principal variables in clinical trials and with their correlation with the clinical main outcomes.

 

120 minutes
Online based learning
English language
Certificate of Achievement
500 €
REGISTER NOW

AUTHORS

avatar

Josep Maria Castel

Universitat Autònoma de Barcelona

avatar

Dr. Antònia Agustí

Universitat Autònoma de Barcelona


avatar

Dr. Xavier Vidal

Universitat Autònoma de Barcelona

avatar

Dr. Montse Bosche

Universitat Autònoma de Barcelona




COMPANIES OFFER

Short courses can be included in a training package for your team!


NEED TO TALK TO US?

+33 5 47 30 42 69

Monday-Friday / 9.00am-6.00pm CET

 

Supported By

IMI logo EU logo efpia logo

Created By

Eu2P Partners